comscore What scientists know about the risk of breakthrough COVID-19 deaths | Honolulu Star-Advertiser

What scientists know about the risk of breakthrough COVID-19 deaths

Honolulu Star-Advertiser logo
Unlimited access to premium stories for as low as $12.95 /mo.
Get It Now
  • ASSOCIATED PRESS / FEB. 15, 2001
                                Then-Secretary of State Colin Powell looks on as President Bush addresses State Department employees at the State Department in Washington in 2001. Powell has died from COVID-19 complications at age 84.

    ASSOCIATED PRESS / FEB. 15, 2001

    Then-Secretary of State Colin Powell looks on as President Bush addresses State Department employees at the State Department in Washington in 2001. Powell has died from COVID-19 complications at age 84.

The death of former U.S. Secretary of State Colin Powell today from complications of COVID-19 has provided fuel for vaccine skeptics and opponents, who immediately seized on the news that Powell had been vaccinated to stoke doubts about the effectiveness of the vaccines.

But Powell’s immune system had quite likely been weakened by multiple myeloma, a cancer of white blood cells. Both the disease and the treatment can make people more susceptible to infections.

His age, 84, may also have increased his risk, scientists said.

Powell received his second dose of the Pfizer-BioNTech vaccine in February, said Peggy Cifrino, his longtime aide. He had been scheduled for a booster last week but fell ill before he received it, she said.

Powell had also undergone treatment for early-stage Parkinson’s disease, she said.

Although Powell’s death is a high-profile tragedy, scientists emphasized that it should not undermine confidence in the COVID vaccines, which drastically reduce the odds of severe disease and death.

“Nothing is 100% effective,” said Dr. Paul Offit, director of the Vaccine Education Center at Children’s Hospital of Philadelphia. “The point of getting a vaccine is that you want to know that the benefits clearly and definitively outweigh the risks. And we know that for this vaccine.”

The vaccines are highly effective, even against the more contagious delta variant, which is now responsible for nearly all coronavirus infections in the United States. People who are fully vaccinated are roughly one-tenth as likely to be hospitalized and even less likely to die from COVID than those who are unvaccinated, according to a recent study from the Centers for Disease Control and Prevention.

A New York Times analysis of data from 40 states found that fully vaccinated people have accounted for 0.2% to 6% of COVID deaths.

Among the more than 187 million Americans who have been fully vaccinated, there have been 7,178 deaths, according to the CDC. Eighty-five percent of those deaths have been in people 65 or older.

“Breakthrough deaths with vaccinated individuals do occur,” said Dr. Peter Hotez, dean of the National School of Tropical Medicine at Baylor College of Medicine in Houston. “But there are certain groups that are at greater risk.”

Since the beginning of the pandemic, it has been clear that older adults are the most likely to develop severe COVID. They also have less robust immune systems in general and mount a weaker immune response to the vaccines.

In one recent study, which has not yet been reviewed by experts, researchers found that residents of Canadian long-term care homes, who had a median age of 88, produced levels of neutralizing antibodies roughly fivefold to sixfold lower after vaccination than did staff members, who had a median age of 47.

“This puts them at risk for not only getting infected by COVID but also having severe consequences,” said Anne-Claude Gingras, a senior investigator at the Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital in Toronto and lead author of the study.

Powell had also undergone treatment for multiple myeloma, a cancer of plasma cells, which are a type of white blood cell. Plasma cells make antibodies and thus play a critical role in the immune system.

Both the disease and the treatment — which may include chemotherapy, immunotherapy and steroids — can leave patients more vulnerable to infections.

“Colin was undergoing treatment for multiple myeloma but seemed to be responding well,” Kathy Giusti, who founded the Multiple Myeloma Research Foundation and met Powell when he spoke at a foundation event, said in a statement. “Immunosuppression is a well-known side effect of cancer treatment and a reminder that as patients, we are at high risk, especially if also over 65 years of age.”

Vaccines are also likely to be less effective in people with multiple myeloma.

“The treatments we’re using are indiscriminately knocking off both the malignant and the normal immune cells,” said Dr. James Berenson, medical and scientific director of the Institute for Myeloma and Bone Cancer Research in West Hollywood, California.

That puts patients “at double risk for getting no response to a vaccination and also not responding as well once they get the disease,” he added.

In a study published in July, Berenson and his colleagues found that just 45% of those with active multiple myeloma “developed an adequate response” after receiving the Pfizer or Moderna vaccines.

People who received the Pfizer vaccine had lower antibody levels than Moderna recipients, on average, the researchers found. Older patients and those who were not yet in complete remission also had lower antibody levels.

It is unclear what kind of treatment Powell received for his multiple myeloma or whether he was in full remission. But even patients who are in remission may have compromised immune systems, Berenson said.

“They usually — not in all cases, but usually — maintain an immune-suppressed state even if they’ve had a good response to their treatment,” Berenson said. “Their antibody levels in most cases don’t go back up to normal.”

In a new study today in the journal Cancer Cell, researchers report that some people with multiple myeloma also have weak T cell responses after vaccination. T cells can help reduce the severity of disease in people who contract the virus.

The study included 44 people with multiple myeloma who were at least two weeks past their second Pfizer or Moderna shot. Seventeen of those people produced no detectable antibodies against the virus after vaccination. These patients had significantly fewer helper T cells, which activate other parts of the immune response, to the virus compared with multiple myeloma patients who had produced antibodies after vaccination.

The good news, said Dr. Samir Parekh, a hematologist at the Icahn School of Medicine at Mount Sinai Hospital in New York City and who led the research, is that research suggests that booster shots “are looking extremely promising” for people with multiple myeloma.

“Patients who haven’t received them should do that immediately,” he said.

The best way to protect older adults and others with compromised immune systems is for everyone else to be vaccinated, said Dr. Ashish Jha, dean of the Brown University School of Public Health.

“When there are large numbers of infections happening in the community, it spills over into vaccinated people,” he said. “And the vulnerable are really at risk.”


This article originally appeared in The New York Times.

Comments (6)

By participating in online discussions you acknowledge that you have agreed to the Terms of Service. An insightful discussion of ideas and viewpoints is encouraged, but comments must be civil and in good taste, with no personal attacks. If your comments are inappropriate, you may be banned from posting. Report comments if you believe they do not follow our guidelines.

Having trouble with comments? Learn more here.

Click here to see our full coverage of the coronavirus outbreak. Submit your coronavirus news tip.

Be the first to know
Get web push notifications from Star-Advertiser when the next breaking story happens — it's FREE! You just need a supported web browser.
Subscribe for this feature

Scroll Up